We are not pursuing a Paxil action and are not aware of any other actions that are ongoing.
We had a Paxil class action on the go many years ago, however, it was specifically limited to complications relating to withdrawal or reduction of dosage.
We alleged inadequate warnings in respect of side effects that would be experienced by patients when reducing or terminating dosage.
Our action really didn't go anywhere as we were piggybacking on an action in the USA.
The USA action stalled as certification was denied in California and then at the Federal Court.
The action that had been commenced by us was as a follow-up to an action that had been commenced by Poyner, Baxter law firm in Vancouver, British Columbia. The Poyner, Baxter action was dismissed/discontinued and our action fell dormant.
Statement of Claim
Click Here
to Read the Statement of Claim
Overview of Claim
A Statement of Claim was issued in the Ontario Superior Court
of Justice on May 2, 2002.
The Statement of Claim names GlaxoSmithKline PLC and GlaxoSmithKline
Inc. as Defendants.
The claim alleges that the pain and suffering experienced
by each of the thousands of Paxil users is a direct result of the failure by
GlaxoSmithKline to warn users of the addictive nature of Paxil, its inducement
of physical and psychological dependency, and its infliction of dependency/withdrawal
reactions when the dosage is terminated or reduced.
The claim further alleges that Paxil caused some people to
experience serious and unexpected dependency/withdrawal reactions. These reactions
were and are unexpected to the patient and prescribing physicians because GlaxoSmithKline
has failed to properly warn of these possible effects.
We are compiling a database of individuals who have been prescribed
Paxil who are or have experienced dependency/withdrawal reactions when the dosage
was terminated or reduced.
If you have not contacted us, we would appreciate hearing
from you as it may assist us in pursuing this claim.
You may contact us by e-mail, telephone, mail, courier, fax,
etc.
|
